Shots:
- Iktos will leverage its de novo generative design technology to be used in a structure-enabled context, facilitating the rapid & cost-effective design of Merck KGaA’s drug discovery program
- The collaboration follows the previous agreement of the companies signed in 2019. Merck KGaA is utilizing Iktos’ de novo design software platform Makya for MPO
- Iktos’ AI technology is based on deep generative models that help bring speed & efficiency to the drug discovery process by automatically designing virtual novel molecules having desired activities for treating a disease
Click here to read the full press release/ article | Ref: Businesswire | Image: CIO.com
The post Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design first appeared on PharmaShots.
